Date: 2016-04-20
Type of information: Series C financing round
Company: Enterome Bioscience (France)
Investors: Seventure (France) Lundbeckfond Venture (Denmark) Nestlé Health Science (Switzerland)
Amount: €14.5 million
Funding type: series C financing round
Planned used: Enterome Bioscience will use the funds raised to advance the development of its lead drug candidate EB 018 into first clinical studies during 2016 as a potential treatment for inflammatory bowel diseases (IBD). This novel small molecule FimH antagonist has just been licensed from Vertex Pharmaceuticals. EB 018 specifically targets Adherent Invasive Escherichia coli (AIEC) proliferation in the gut, one of the main causes of inflammatory colitis in IBD sufferers. In the diagnostics space, Enterome will pursue its development efforts in IBD and other microbiome-related diseases, where its unique technologies and insights can be leveraged on its own or under partnerships with diagnostic and pharmaceutical companies. Enterome will also use the funds to advance therapeutic programs in Immuno-Oncology.
Others: * On April 20, 2016, Enterome Bioscience announced that it has raised €14.5 million in a Series C financing
round. The round was led by existing investors, such as Seventure (including from its new Health for Life Capital fund) and Lundbeckfond Ventures, and included new investors. Nestlé Health Science also participated in the round as a new strategic investor.
Enterome Bioscience was established in 2012 in France to develop the discoveries made by the INRA metagenomic platform. The Company has raised a total of €32 million from leading venture capital investors (Seventure Partners, Lundbeckfond Ventures & Omnes Capital) and strategic investors (Nestlé Health Science, Shire & INRA transfer).
Therapeutic area: Digestive diseases - Gastrointestinal diseases - Inflammatory diseases
